Clinical Trial Update: Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the combination of cabozantinib S-malate and nivolumab in patients with advanced, recurrent, or metastatic endometrial cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Uterine Carcinosarcoma

Drugs mentioned

• Cabozantinib S-Malate (cabozantinib)
• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING